AbbVie Inc Acquired IPR&D And Milestones Expense To Have Unfavorable Impact Of $0.15 To Both Share And Adj Share In Q2
Portfolio Pulse from Happy Mohamed
AbbVie Inc has acquired IPR&D and Milestones Expense, which is expected to have an unfavorable impact of $0.15 to both share and adjusted share in Q2.
July 06, 2023 | 8:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AbbVie's recent acquisition is expected to negatively impact its share and adjusted share by $0.15 in Q2.
AbbVie's acquisition of IPR&D and Milestones Expense is expected to have an unfavorable impact on its share and adjusted share in Q2. This could potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100